Display options
Cite
Beauvarlet J, Nath Das R, Alvarez-Valadez K, et al. Triarylpyridine Compounds and Chloroquine Act in Concert to Trigger Lysosomal Membrane Permeabilization and Cell Death in Cancer Cells. Cancers (Basel). 2020;12(6)doi: 10.3390/cancers12061621.
Beauvarlet, J., Nath Das, R., Alvarez-Valadez, K., Martins, I., Muller, A., Darbo, E., Richard, E., Soubeyran, P., Kroemer, G., Guillon, J., Mergny, J. L., & Djavaheri-Mergny, M. (2020). Triarylpyridine Compounds and Chloroquine Act in Concert to Trigger Lysosomal Membrane Permeabilization and Cell Death in Cancer Cells. Cancers, 12(6), . https://doi.org/10.3390/cancers12061621
Beauvarlet, Jennifer, et al. "Triarylpyridine Compounds and Chloroquine Act in Concert to Trigger Lysosomal Membrane Permeabilization and Cell Death in Cancer Cells." Cancers vol. 12,6 (2020). doi: https://doi.org/10.3390/cancers12061621
Beauvarlet J, Nath Das R, Alvarez-Valadez K, Martins I, Muller A, Darbo E, Richard E, Soubeyran P, Kroemer G, Guillon J, Mergny JL, Djavaheri-Mergny M. Triarylpyridine Compounds and Chloroquine Act in Concert to Trigger Lysosomal Membrane Permeabilization and Cell Death in Cancer Cells. Cancers (Basel). 2020 Jun 18;12(6). doi: 10.3390/cancers12061621. PMID: 32570977; PMCID: PMC7352983.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jun 18;12(6). doi: 10.3390/cancers12061621.

Triarylpyridine Compounds and Chloroquine Act in Concert to Trigger Lysosomal Membrane Permeabilization and Cell Death in Cancer Cells.

Cancers

Jennifer Beauvarlet, Rabindra Nath Das, Karla Alvarez-Valadez, Isabelle Martins, Alexandra Muller, Elodie Darbo, Elodie Richard, Pierre Soubeyran, Guido Kroemer, Jean Guillon, Jean-Louis Mergny, Mojgan Djavaheri-Mergny

Affiliations

  1. Institut Bergonié, INSERM U1218, Université de Bordeaux, 33000 Bordeaux, France.
  2. ARNA Laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR 5320, 33000 Bordeaux, France.
  3. Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94805 Villejuif, France.
  4. Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université de Paris, Equipe 11 labellisée par la Ligue contre le Cancer, 75006 Paris, France.
  5. Gustave Roussy Comprehensive Cancer Institute, 94805 Villejuif, France.
  6. Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France.
  7. Suzhou Institute for Systems Medicine, Chinese Academy of Sciences, Suzhou 215123, China.
  8. Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.

PMID: 32570977 PMCID: PMC7352983 DOI: 10.3390/cancers12061621

Abstract

Lysosomes play a key role in regulating cell death in response to cancer therapies, yet little is known on the possible role of lysosomes in the therapeutic efficacy of G-quadruplex DNA ligands (G4L) in cancer cells. Here, we investigate the relationship between the modulation of lysosomal membrane damage and the degree to which cancer cells respond to the cytotoxic effects of G-quadruplex ligands belonging to the triarylpyridine family. Our results reveal that the lead compound of this family,

Keywords: G-quadruplex ligand; Lysosome; cancer; cell death; lysosomal membrane permeabilization; resistance to therapy; triarylpyridine compounds

References

  1. Chem Commun (Camb). 2012 Jan 21;48(6):874-6 - PubMed
  2. J Am Chem Soc. 2007 Feb 14;129(6):1502-3 - PubMed
  3. Cancer Res. 2009 Oct 1;69(19):7653-61 - PubMed
  4. Ann N Y Acad Sci. 2016 May;1371(1):45-54 - PubMed
  5. Cancer Res. 2004 Aug 1;64(15):5301-10 - PubMed
  6. Annu Rev Physiol. 2015;77:57-80 - PubMed
  7. Drug Metab Dispos. 2013 Apr;41(4):897-905 - PubMed
  8. J Cell Sci. 2013 May 1;126(Pt 9):1905-12 - PubMed
  9. Nucleic Acids Res. 2019 Apr 8;47(6):2739-2756 - PubMed
  10. Oncogene. 2008 Oct 27;27(50):6434-51 - PubMed
  11. Mitochondrion. 2014 Nov;19 Pt A:49-57 - PubMed
  12. Mol Cancer Ther. 2007 Jun;6(6):1804-13 - PubMed
  13. J Biol Chem. 2017 May 19;292(20):8424-8435 - PubMed
  14. Integr Biol (Camb). 2013 Oct;5(10):1217-28 - PubMed
  15. PLoS Pathog. 2017 Feb 13;13(2):e1006217 - PubMed
  16. Genes Dev. 2007 Nov 15;21(22):2861-73 - PubMed
  17. Oncogene. 2003 Jun 19;22(25):3927-36 - PubMed
  18. Oncotarget. 2015 Jan 20;6(2):1143-56 - PubMed
  19. Eur Biophys J. 2008 Oct;37(8):1317-28 - PubMed
  20. Cancer Res. 1992 Jul 15;52(14):4000-8 - PubMed
  21. Autophagy. 2012 Jun;8(6):903-14 - PubMed
  22. Phys Chem Chem Phys. 2017 Jul 14;19(26):17404-17410 - PubMed
  23. J Cell Biol. 2015 Jun 22;209(6):879-94 - PubMed
  24. Curr Pharm Des. 2016;22(44):6612-6624 - PubMed
  25. Mol Cell Oncol. 2019 May 8;6(4):1604047 - PubMed
  26. J Mol Cell Biol. 2013 Aug;5(4):214-26 - PubMed
  27. Leuk Res. 2001 May;25(5):395-405 - PubMed
  28. Amino Acids. 2011 Feb;40(2):533-42 - PubMed
  29. Trends Biotechnol. 2017 Oct;35(10):997-1013 - PubMed
  30. Nat Commun. 2015 Sep 09;6:8178 - PubMed
  31. Nucleic Acids Res. 2012 Jul;40(12):5432-47 - PubMed
  32. Biochimie. 2015 Aug;115:194-202 - PubMed
  33. Nat Med. 2016 Mar;22(3):270-7 - PubMed
  34. Bioanalysis. 2009 Nov;1(8):1445-59 - PubMed
  35. Org Biomol Chem. 2011 Sep 7;9(17):6154-62 - PubMed
  36. Science. 2011 Jun 17;332(6036):1429-33 - PubMed
  37. J Pharmacol Exp Ther. 2006 Jan;316(1):242-7 - PubMed
  38. J Exp Med. 2003 May 19;197(10):1323-34 - PubMed
  39. Antioxid Redox Signal. 2012 Sep 1;17(5):766-74 - PubMed
  40. Nat Rev Cancer. 2005 Nov;5(11):886-97 - PubMed
  41. Autophagy. 2015;11(8):1408-24 - PubMed
  42. Nat Cell Biol. 2013 Jul;15(7):713-20 - PubMed
  43. Oncogene. 2013 Apr 18;32(16):1995-2004 - PubMed
  44. Cancer Cell. 2013 Sep 9;24(3):379-93 - PubMed

Publication Types

Grant support